Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
Oxaliplatin
Universal Integrated
Previously Treated Metastatic Non-Small Cell Lung Cancer
1 trial -
Oxaliplatin
Sanofi Pasteur
Uterine Neoplasms
1 trial -
Oxaliplatin
Regeneron UK Limited
Colorectal Cancer
1 trial -
P276-00
Piramal Critical Care B.V.
Melanoma
1 trial -
PACLITAXEL AHCL /ml for Head and neck squamous cell carcinoma
Ningbo Cancer Hospital
Head and neck squamous cell carcinoma
1 trial -
PARP inhibitor 2X-121
Allarity Therapeutics
Metastatic Breast Cancer
1 trial -
PAUF-I
Lacuna Pharma Pty Ltd
Advanced and/or metastatic pancreatic adenocarcinoma
1 trial -
PAXALISIB
KAZIA THERAPEUTICS LTD
Primary Central Nervous System Lymphoma
1 trial -
PBCAR20A
Chongqing Precision Biotech Co., Ltd
Non-Hodgkin's Lymphoma, Relapsed
1 trial -
PC-IIT-003
The First People's Hospital of Lianyungang
Pancreatic Cancer
1 trial -
PC14586
PMV Pharmaceuticals
Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation
1 trial -
PCAR-019 (anti-CD19 CAR-T cells)
The First People's Hospital of Lianyungang
Acute Lymphocytic Leukemia
1 trial -
PCS6422 and capecitabine
Processa Pharmaceuticals
Breast Cancer
1 trial -
PD -1/PD-L1 monoclonal antibody plus radiotherapy and liver transplantation
The First People's Hospital of Lianyungang
Locally Advanced Perihilar Cholangiocarcinoma
1 trial -
PD 0332991
Pfizer
Breast Cancer
1 trial -
PD-1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Rectal Cancer Patients
1 trial -
PD-1 Inhibitor plus Chemotherapy
Sichuan University
Esophageal Squamous Cell Carcinoma
1 trial -
PD-1 antibody Sintilimab
The First People's Hospital of Lianyungang
Multiple Primary Lung Cancers
1 trial -
PD-1 inhbitor+SHR0302
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-Small Cell Lung Cancer
1 trial -
PD-1/CTLA-4 Dual Functional Antibody
The First People's Hospital of Lianyungang
Bile Duct Carcinoma
1 trial -
PD-1/PD-L1 inhibitors
BEONE MEDICINES AUS PTY LTD
Borderline Resectable Carcinoma
1 trial -
PD-1inhibitor
Shanghai Chest Hospital
Esophageal Squamous Cell Carcinoma
1 trial -
PD-L1, PD-L2 peptides with Montanide ISA51
IO Biotech
Chronic Lymphocytic Leukemia
1 trial -
PDC-LUNG-101
Lacuna Pharma Pty Ltd
Non-small-cell lung cancer
1 trial -
PEGFILGRASTIM , Rinatabart Sesutecan
Genmab A/S
Locally advanced or metastatic Non-Small Cell Lung Cancer
1 trial -
PEGINTERFERON ALFA-2A for Metastatic Melanoma
Disc Medicine
Metastatic Melanoma
1 trial -
PEGPH20
HALOZYME THERAPEUTICS, INC.
Metastatic Pancreatic Adenocarcinoma
1 trial -
PEGPH20
HALOZYME THERAPEUTICS, INC.
Pancreatic Ductal Adenocarcinoma
1 trial -
PEGPH20
HALOZYME THERAPEUTICS, INC.
Metastatic Pancreatic Cancer
1 trial -
PELICAN-IPC 2015-016
The George Institute
Breast cancer
1 trial -
PEMBROLIZUMAB
Pari Pharma GmbH
Kaposi's sarcoma
1 trial -
PF-03446962
Pfizer
Carcinoma, Hepatocellular
1 trial -
PF-07850327 round
Pfizer Australia Pty Ltd
ADVANCED OR METASTATIC BREAST CANCER
1 trial -
PFL721CI101
Pierre Fabre Medicament
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial -
PH-ICKPD1-02/21
Philogen S.p.A.
Patients with diagnosis of unresectable clinical stage III or IV metastatic melanoma, with presence of injectable cutaneous, subcutaneous or nodal lesions and resistant to or progressing upon anti-PD1 immunotherapy
1 trial -
PH-L19TNFSARC-03/18
Philogen S.p.A.
Unresectable and/or metastatic soft-tissue sarcoma after failure of at least two prior systemic therapy regimens.
1 trial -
PHERFLOT
The George Institute
HER2-positive, localized esophagogastric adenocarcinoma
1 trial -
PHITAH
Lxo Ireland Designated Activity Company
Basal Cell Carcinoma
1 trial -
PI-88
Biotech Pharmaceutical Co.,
Lung Cancer
1 trial -
PI3K inhibitor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lymphoma, T-Cell
1 trial -
PIK3CA inhibitor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Neoplasm
1 trial -
PIRTOBRUTINIB
Fondazione Telethon ETS
Mantle Cell Lymphoma
1 trial -
PIVEKIMAB SUNIRINE
AbbVie Deutschland GmbH & Co. KG
Acute Myeloid Leukemia and other blood cancers
1 trial -
PLD and Carboplatin
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
PM14, IRINOTECAN
Lacuna Pharma Pty Ltd
Patients with Selected Advanced Solid Tumors
1 trial -
PM14-A-001-17
Lacuna Pharma Pty Ltd
Advanced Solid Tumors
1 trial -
PM8002
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Locally Advanced Non-Small Cell Lung Cancer
1 trial -
POINT
Fondazione Telethon ETS
Adult patients affected by recurrent/metastatic, platinum resistant nasopharyngeal cancer
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.